Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Moxonidine in Patients Undergoing Vascular Surgery

This study has been terminated.
(Study was stopped after pre-definied interim analysis because of no effects)
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: October 25, 2005
Last updated: November 9, 2009
Last verified: November 2009
Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Condition Intervention Phase
Cardiac Disease
Vascular Surgery
Drug: moxonidine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • over-all mortality [ Time Frame: 30 days and 12 months ]

Secondary Outcome Measures:
  • Ischemia detected by Holter-ECG ST alterations or troponin T elevation [ Time Frame: 7 days ]

Enrollment: 141
Study Start Date: November 2002
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: I
moxonidine group
Drug: moxonidine
moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
Other Name: Physiotens
Placebo Comparator: II
placebo group
Drug: moxonidine
moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
Other Name: Physiotens


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • abdominal aortic or peripheral vascular surgery

Exclusion Criteria:

  • unstable angina,
  • severe symptomatic heart failure (NYHA IV)
  • systolic blood pressure at rest < 100 mmHg
  • bradycardia (<50/min)
  • higher grade AV heart block
  • creatinine clearance < 30 ml/min
  • pregnancy
  • no consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00244504

University hospital
Basel, CH, Switzerland, 4000
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Miodrag Filipovic, PD Dr. University Hospital, Basel, Switzerland
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: PD Dr. M. Filipovic, Co-Head of Cardiothoracic Anaesthesia Identifier: NCT00244504     History of Changes
Other Study ID Numbers: 158/01
Study First Received: October 25, 2005
Last Updated: November 9, 2009

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases
Antihypertensive Agents processed this record on May 25, 2017